with the patients and with their relatives to give them confidence.
Science and Medicine has greatly changed since the time of Georg Wilhelm Leibniz. Nowadays, collaboration between many investigators, many disciplines and many institutions is essential. CESAR, the Central European Society for Anticancer Drug Research was founded to promote such collaboration. The annual meetings of CESAR, like the meeting from June 12 -14, 2008 in Göttingen, Germany, provide a forum for translational cancer research bringing together molecular biology, chemistry, pharmacy, pharmacology and clinical research. And still, the CESAR meetings like the Meeting in 2008 are personal enough to allow each participant of the meeting to get an overview about the whole action of the CESAR group.
The three main topics of the meeting were drug resistance mechanisms, individualized therapy and anticancer drug development from drug discovery to first-in-man trials. One may simply say that every case of death from cancer is a case of drug resistance and drug resistance was the topic of the first session of the CESAR meeting in June 2008. The session started with an overview given by Walter Jäger from Vienna, Austria, on mechanisms of drug resistance related to transmembrane drug transport. The slides provided a very comprehensive overview of the different efflux and influx transporters, and their regulation by genetic and environmental factors. Understanding these mechanisms of resistance is important not only to develop and to achieve a better understanding of the combination of anticancer therapies but also to avoid harmful drug interactions in the practice of oncolytic drug therapy. When the drug has entered the cell, other mechanisms of resistance play a role. Recent research data on that were provided by Robert Mader from Vienna. On the example of fluoropyrimidines, Robert Mader showed how multiple mecha-nisms like intracellular bio-activation, gene regulation by DNA methylation, DNA repair, apoptosis, and other changes in signaling can contribute to cellular resistance. Resistance to targeted therapies was the topic of Doriano Fabbro from Basel, Switzerland. Doriano Fabbro provided a broad overview of the principles of targeted therapies focusing on small molecular kinase inhibitors. In many instances molecular mechanisms could be elucidated as structural variations in the drug targets and other kinase inhibitors or interventions at other steps of the signaling cascades still could be used for therapy. In this sense, the analysis and the clinical handling of resistance to kinase inhibitors is an excellent example of individualized therapy based on molecular diagnostics.
Individualized therapy was also the topic of the afternoon session. Jacques Robert from Bordeaux, France, presented an example how the lysine751-to-glycin variant affected the outcome of a clinical trial on 5-FU and oxaliplatin in colorectal cancer. In the second part of his lecture, Jacques Robert gave an overview and perspectives on how clinical pharmacogenomic research can be combined with functional and genomic research in human tissue banks, human lymphoblastoid cell lines and tumor cell lines. Often, only by a combination of several of these approaches can the relevant genomic variations be identified and understood. The lecture of Max Scheulen started with an overview of the definitions of biomarkers, surrogate end points, clinical endpoints and clinical response. The lecture showed the pros and cons of the different parameters showing that further methodical developments are not only needed concerning biomarkers but also concerning clinical response markers. The lecture illustrated the value of biomarkers on examples like cytostatic drug concentrations, in vivo PET, and side effects of drug therapy like erlotinib induced folliculitis of the skin. The last lecture of the day by Jürgen Brockmöller focused on genetic variation in the drug metabolizing enzyme CYP2D6 as a paradigm of a genetic polymorphism. That enzyme is relevant for many drugs in supportive cancer therapy like tropisetron and ondansetron, but as recognized recently, it can be a most important determinant for the response to the selective estrogen receptor modifier tamoxifen. Jürgen Brockmöller emphasized that clinical pharmacogenetic research in oncology should not only be of interest for molecular research but should finally be directed to save lives of cancer patients. Concerning tamoxifen, he gave the recommendation that tamoxifen should not be prescribed without prior genotyping anymore and should then in general not be prescribed to genetically poor metabolizers of CYP2D6. And in addition, it should not be given in long-term co-medication with CYP2D6 inhibitors.
Basic research in pharmacology and oncology frequently generates proposals for new therapies in man, which are usually now types of drug therapies. In this situation, a solid understanding of the early steps of drug development and GMP production is substantial to avoid, on the one hand, jumping prematurely into clinical trials. But on the other hand, clinical trials on promising new approaches should also not be delayed unnecessarily. And therefore, the sessions on Friday were devoted to preclinical and early clinical drug development in oncology. The first lecture was an excellent overview given by Bernhard Böhm from Biberach, Germany, on preclinical drug development and on GMP production. The following lecture by Olivier Jankowitch from Vienna, Austria, continued with that theme and illustrated the specific processes of the development of protein drugs on the example of the development of vaccines against bacterial pathogens. On the example of the epothilone-type tubulin inhibitors, Jens Hoffmann from Berlin illustrated the way from drug discovery to Phase I and Phase II studies. More than 350 derivatives of Preface the naturally occurring tubulin depolymerization inhibitor epothilone B were screened concerning activity and toxicity mostly by cell culture models. One most promising derivative, sagopilone, appeared to be active in a wide spectrum of human tumor xenografts in nude mice. Interestingly, the drug was even effective in MDR1 over expressing multidrug resistant tumors.
Based on his practical experience and based on the relevant EMEA guidelines, Silvio Wuschko from Seibersdorf, Austria, presented a review of the requirements on pre-clinical evaluation of anticancer medicinal products. Bernhard Hauns from Konstanz summarized current chances and challenges in early clinical drug development of anticancer drugs. Safety of the study participants is a main issue after the TeGenero case. Optimized planning, conduct, analysis and interpretation of preclinical and clinical Phase I trials may sometimes help saving expensive Phase II and Phase III trials. The discussion about pre-launch versus post launch expansion of the indications of new drugs was also interesting. Design of first-in-man trials in oncology was also the topic of the lecture delivered by Klaus Mross, Freiburg, Germany. Different modes of dose escalation were compared. Individual dose escalation is still not commonly accepted but if performed in a limited controlled fashion this may provide several advantages. Biomarkers are most important in these first-in-man trials but as he explained, nothing is better than objective response.
The meeting ended on Saturday with 12 short lectures and several posters, some but not all contributions of the symposium are summarized as abstracts in this volume of the Journal. The Saturday session was well attended and there were active discussions. Topics of these presentations included the broad spectrum of experimental cancer research and human pharmacology of anticancer drugs. Topics included mechanisms of tumor growth and progression, pharmaceutical chemistry of potential new anticancer drugs, clinical pharmacology and pharmacokinetics of anticancer drugs and side effects of drug therapies. Besides being the annual meeting of CESAR, the June 2008 symposium also served as an important educational element within the Göttingen Graduate College on Cancer Pharmaco-Genomics (www.gcpg.de). In this context, the symposium provided an excellent introduction into preclinical and clinical drug development. Participants of the meeting are looking forward to the next CESAR symposia which again can be recommended as an excellent introduction to translational and clinical cancer research.
J. Brockmöller, Göttingen, Germany, D. Sehrt, Göttingen, Germany, and M.E. Scheulen, Essen, Germany Modulation of the efficacy of temozolomide and dacarbazine melanoma treatment by DNA-repair factors in vivo and in vitro*
Introduction
The incidence of cutaneous melanoma is rising more rapidly than that for any other malignant tumor. If distant metastases occur, the annual survival falls below 20% [Keilholz et al. 2001] . Temozolomide (TMZ) and dacarbazine (DTIC) as monochemotherapy, are considered the standard therapy for metastasized and surgically unresectable melanoma. An approximately 15% objective response rate can be achieved with DTIC [Serrone et al. 2000] .
The chemotherapeutic agents TMZ and DTIC are pro-drugs of the cytotoxic agent 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC) [Serrone et al. 2000] . MTIC possesses alkylating activity and generates methyl-DNA-adducts. The most crucial methyl-DNA-adduct for the efficacy of TMZ/ DTIC treatment is O 6 -methylguanine (O 6 -meG). This lesion can be repaired by the enzyme O 6 -methylguanine-DNA-methyltransferase (MGMT). The MGMT transfers the methyl group in an auto-inactivating process to an internal cysteine acceptor residue [Newlands et al. 1997] .
If the methyl group at the O 6 position of guanine is not removed by MGMT the O 6 -meG adduct leads to mis-pairing with thymine. Guanine-thymine (GT) mismatch replication errors are normally corrected by the mismatch repair system (MMR). In MMR the MutSa-complex heterodimer (MSH2, MSH6) binds to the mismatch and recruits an additional heterodimer, the MutLa-complex (MLH1, PMS2), which initiates the repair process by activating exonuclease-mediated degradation of DNA. Futile attempts to correct these mismatches lead to long-lived nicks in the DNA and finally result in apoptosis of the cell [Kaina et al. 2007] .
Thus, the success of a TMZ/DTIC therapy may strongly depend on low MGMT repair and on high mismatch repair.
Material and Methods
Clinical data were obtained from 51 melanoma patients treated with TMZ or DTIC. RNA was isolated from whole blood samples taken prior to therapy or during a therapy-free interval using PAXgene (Qiagen, Hilden, Germany). cDNA was obtained from the mRNA by reverse transcription polymerase chain reaction (RT-PCR) (RevertAidTM H Minus First Strand cDNA Synthesis Kit, FERMENTAS, ST.Leon-Rot) and used to quantify mRNA expression levels by real time PCR (LightCycler, Roche, Mannheim). Gene expression levels were normalized to the housekeeping gene GAPDH.
Similarly genomic DNA was isolated (QIAmp Blood Kit, QIAGEN, Hilden, Germany). The entire coding regions including splice sides of the MGMT, MLH1, and MSH2 genes were sequenced of each patient (ABI Prism ® 310 Genetic Analyzer, Darmstadt, Germany). The genes were sequenced in order to detect new or to confirm known single nucleotide polymorphisms (SNPs).
To determine the methylation status within the promoter regions of these genes ge- In addition, we tested the sensitivity of five different melanoma cell lines, established from human melanoma metastases, against TMZ (kindly provided by Schering Plough, Kenilworth, NY, USA). After treatment with various concentrations of TMZ the melanoma cell survival was determined using the CellTiter 96 ® Non-Radioactive Cell Proliferation Assay (PROMEGA, Madison, WI). Two treatment strategies were followed: Cells were treated once with TMZ and incubated for five days (Table 1A) or cells were treated with TMZ every 24 hours for a period of five days by exchanging the TMZ containing medium daily (Table 1B) .
Results
In preliminary analyses of 23 patients inter-individual variations were observed in the individual baseline expression levels of the MGMT, MLH1, and MSH2 repair enzymes in peripheral blood lymphocytes. Several genetic polymorphisms were confirmed, and five polymorphisms in MLH1 newly identified: C36985867A, C36993642del, G37010441A, T37030079C, and CTT37032185del. For all possible pairs of the detected SNPs the linkage disequilibrium across the MGMT, MLH1, and, MSH2 genes were investigated. Only one polymorphism (MLH1: I219V) showed a reduced MLH1 gene expression in association with G allele presence.
The methylation status of the gene promoters correlated well with gene expression. When all data from all 51 patients are available we will correlate the gene expression status with TMZ/DTIC treatment outcome and side effects.
In vitro experiments aim at identifying DNA repair-associated factors that modulate the cellular TMZ sensitivity. We hypothesized that a prolonged TMZ treatment should result in a higher cellular sensitivity, by depleting MGMT, compared to a single dose treatment. Table 1C shows the TMZ concentrations identified that lead to a~50% reduction in cell survival (D 50 ) of five different melanoma cell lines. As expected, the two melanoma cell lines KAII and LIBR showed lower D 50 values after an escalated TMZ treatment than after the single dose treatment. Surprisingly, resistance of the three other The most resistant cell line, MelC, was the only cell line that showed a base line MGMT mRNA expression. In neither of the tested cell lines an increase or decrease in the mRNA expression of MGMT, MLH1, and MSH2 could be found within 24 hours after TMZ treatment.
In all cell lines the MLH1 and MSH2 promoter regions were not methylated, whereas the promoter of the MGMT gene was methylated in four out of five cell lines. Only in the cell line MelC the MGMT promoter region was nonmethylated. These findings nicely correlate with the base line mRNA expression.
Conclusion
Melanoma resistance to TMZ or DTIC treatment is a major problem. Our in vivo analyzes of 51 melanoma patients can contribute to the understanding how host-DNA repair factors (MGMT, MLH1, MSH2 gene expression) may be modulated by SNPs or promoter methylation and may, thus, modulate treatment outcome or side effects in melanoma patients.
Our finding that 3 out of 5 melanoma cell lines showed an unexpected increased resistance to TMZ in an escalated dose schedule with only one cell line expressing MGMT indicates that yet further resistance mechanisms must exist. Our in vitro studies aim at identifying new TMZ resistance mechanisms.
Introduction
Selective serotonin receptor type 3 (5-HT 3 ) antagonists are successfully used to reduce chemotherapy-induced nausea and vomiting. The addition of glucocorticoids to 5-HT 3 antagonists further reduces nausea and vomiting [The Italian Group for Antiemetic Research 1995] . However, the mechanisms behind the synergistic effect of glucocorticoids and 5-HT 3 receptor antagonists are not known. One explanation is that glucocorticoids may reduce the chemotherapy-induced release of serotonin from the enterochromaffin cells of the gut wall, and thus, reduce the stimulation of 5-HT 3 receptors on vagal fibers. Alternatively, glucocorticoids may directly affect the expression of the 5-HT 3 receptors and thus reduce nausea and vomiting.
The 5-HT 3 receptors are serotonin gated Na + /K + -ion-channels of the cys-loop receptor family. The 5-HT 3 receptors are expressed in brain and on peripheral vagal fibers and are involved in the control of gut motility. Five proteins encode for the receptor subunits and assemble the functional 5-HT 3 receptor in various stoichiometries in different tissues. One of the proteins, the 5-HT 3B subunit, determines the properties of the ion channel [Davies et al. 1999 , Dubin et al. 1999 . Other promoters of the 5-HT 3B gene have been reported in humans [Tzvetkov et al. 2007] and functional promoter polymorphisms have been associated with the severity of chemotherapy-induced nausea and vomiting [Meineke et al. 2008 , Tremblay et al. 2003 ]. However, the mechanisms of transcriptional regulation of 5-HT 3B are not well known.
In this study we asked whether glucocorticoids affect the transcription of 5-HT 3B .
Therefore, we analyzed the effect of glucocorticoids on the endogenous expression, the mRNA stability and the proximal promoter activity of 5-HT 3B gene in rat PC-12 cells.
Material and Methods
The rat PC-12 cells are a well established model for assessing the expression of the 5-HT 3 receptor [Hanna et al. 2000] . We analyzed the expression of 5-HT 3A and 5-HT 3B by quantitative RT-PCR using pre-designed TaqMan assays (# Rn00577803_m1 and # Rn00573408_m1; Applied Biosystems, Darmstadt, Germany). The expression was normalized to the expression of the house keeping protein TBP (TATA-box binding protein, assay # Rn01455648_m1 Applied Biosystems).
The mRNA stability was assessed after the cells were treated with 4 µM actinomycin D for 0 -24 hours. The proximal promoter activity was measured using luciferase reporter gene assays. We used constructs containing 2675 bp. from the promoter region (positions 2690 to 15 bp. upstream of the translational start site) and the "core", 246-bp. promoter region (positions 261 to 15 bp. upstream of the translational start site) cloned in the pXP2 luciferase reporter plasmid.
Results
To determine the role of glucocorticoids in 5-HT 3 expression, we first looked for the effect of dexamethasone on the endogenous expression of 5-HT 3B and 5-HT 3A subunits in rat PC-12 cells. The 5-HT 3B expression in- creased with increasing concentrations of dexamethasone. The increase reached 6.3-fold at 1000 nM, but was already more than 4-fold at 10 nM dexamethasone (Figure 1 ). In contrast, 5-HT 3A expression was not significantly affected by dexamethasone. Thus, dexamethasone increased the endogenous expression of the 5-HT 3B subunit selectively.
To interpret the observed increase in 5-HT 3B expression, we tested whether dexamethasone may affect 5-HT 3B mRNA stability. The half-life of 5-HT 3B mRNA was 9.4 ± 1.4 h in the presence and 9.0 ± 1.0 h in the absence of dexamethasone. Also the half-life of 5-HT 3 A did not change after addition of dexamethasone. Thus, the observed increase in 5-HT 3B expression could not be attributed to an increase in mRNA stability caused by dexamethasone.
Next, we tested if dexamethasone affects the activity of the rat 5-HT 3B promoter. We assayed the activity of the 2690-bp fragment and the core, 261-bp-fragment of the proximal 5-HT 3B promoter in PC-12 cells treated with dexamethasone for 24 h before the activity measurement. Promoter activity was detected in the 2690-bp fragment (10.3-fold higher compared to the activity of the empty reporter plasmid) and in the core, 261-bpfragment (23.5-fold higher than the empty vector). However, no significant change in promoter activity of both promoter fragments could be observed between the dexamethasone treated cells compared to those that were non-treated. Thus, dexamethasone do not affect proximal promoter activity of 5-HT 3B .
Conclusion
In this study, we demonstrate that dexamethasone increases the expression of 5-HT 3B , but not of the 5-HT 3A , in PC-12 cells and dexamethasone may thus modulate nausea and vomiting by modulating the stoichiometry of 5-HT 3 receptors. The increased expression cold not be explained by reduced mRNA stability or decreased activity of the proximal 5-HT 3B promoter. The effects of dexamethasone on the 5-HT 3B distal promoter and the resulting effects on the receptor activity remained to be elucidated. Understanding how dexamethasone affects nausea and vomiting may help to develop other antiemetic drugs with reduced side effects compared to dexamethasone. 
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Introduction
Currently, approximately 4,800 organ transplantations are carried out per year and there are about 100,000 transplant patients in Germany who have an increased cancer risk, for example lymphomas, breast cancer and colon cancer. Furthermore, immunosuppressive medications can lead to the development of premalignant or malignant skin cancers. For example, cyclosporin A causes skin cancer in 40% of the transplant patients within 5 years after transplantation, and these include squamous cell carcinoma, basal cell carcinoma and cutaneous melanoma [Bouwes et al. 1996] . Azathioprine and steroids are associated with a moderately increased skin cancer risk but so far no increased skin cancer risk has been reported for sirolimus and everolimus [Euvrard et al. 2004] .
It is generally believed that cyclosporin A, a calcineurin inhibitor, is involved in carcinogenesis is involved in carcinogenesis by promoting tumor growth and metastasis due to the suppressed immune system. In addition, it has been shown that cyclosporin A leads to upregulation of the tumor growth factor TGF-b [Hojo et al. 1999] . On the other hand, cyclosporin A may also affect tumor initiation, as this drug is associated with a decreased DNA repair capability in human keratinocytes [Yarosh et al. 2005] .
Xeroderma pigmentosum (XP) patients have a defective nucleotide excision repair (NER) of UV-induced DNA damages andlike organ transplant patients -have an increased skin cancer risk in skin areas exposed to sunlight [Bootsma et al. 1998 ]. We assessed the influence of cyclosporin A in comparison to the mTOR inhibitor everolimus on the repair of UV-induced DNA damage in normal human fibroblasts and lymphoblasts.
Material and methods
The EBV-immortalized normal human lymphoblast cell line AG10107 and the SV40-immortalized normal human fibroblast cell line GM00637 were obtained from the Corriell Cell Repository (Camden, NJ, USA) and cultured according to the standard protocols. Cyclosporin A and everolimus were dissolved in ethanol and further diluted in culture media. Post-UV cell survival was measured in cyclosporin A-and everolimustreated vs. untreated AG10107 lymphoblasts and GM00637 fibroblasts using MTT assay. Cells pre-incubated 24 h with or without immunosuppressants were UV irradiated (UVC 500 Ultraviolet Crosslinker, Amersham Biosciences, Freiburg, Germany), and then incubated for 48 hours in media with or without immunosuppressive drugs. Cell survival was measured using Promega's CellTiter 96 Non-Radioactive Cell Proliferation Assay afterwards.
To assess the influence of both immunosuppressants on cellular repair, host cell reactivation (HCR) was used [Thoms et al. 2007] . A firefly luciferase reporter gene plasmid, either UV-irradiated or unirradiated was transfected into host cells. After a two day incubation period with or without immunosuppressants, cells were lysed and the luciferase enzyme was measured using Promega's DualLuciferase Reporter Assay System. Host cells can express luciferase enzyme only if they can repair the previously induced UVdamages in the plasmid. Thus, the amount of The elimination of DNA photoproducts was assessed by an ELISA and specific antibodies against cyclobutan-pyrimidine-dimers (CPD). UV-irradiated GM00637 fibroblasts were incubated for different repair times with or without immunosuppressants, then DNA was isolated, coated on a well plate, and the remaining CPDs were measured using specific anti-CPD-antibodies.
Results
Looking at cell survival after UV-irradiation, GM00637 fibroblasts and AG10107 lymphoblasts showed a dose dependent decrease of post UV-cell survival with increasing concentrations of cyclosporin A (e.g. 85% (GM00637) and 76% (AG10107) cell survival with 0.1 µM cyclosporin A). In contrast, everolimus (1 nM -100 nM) did not influence cell survival after UV-irradiation of both GM00637 fibroblasts and AG10107 lymphoblasts (Table 1 left column). Toxic effects of both immunosuppressants were excluded by comparison with unirradiated cells.
Host cell reactivation was used to measure NER capacity. Cyclosporin A led to a dose dependent decrease of firefly luciferase expression, while the firefly luciferase expression of an unirradiated plasmid is not influenced by cyclosporin A. The relative NER capacity, calculated as the ratio of percent expressed luciferase enzyme of irradiated vs. unirradiated plasmid, greatly decreased with increasing cyclosporin A concentrations (Table 1 middle column, top). At 0.2 µM cyclosporin A the cellular NER capacity was reduced to amounts comparable to xeroderma pigmentosum-cells (3 % with GM00637 fibroblasts). In contrast, everolimus (1 nM -1000 nM) did not influence relative NER capacity with increasing concentrations (GM00637: 28%, AG10107:~15%) ( Table 1 middle column, bottom) .
Using an ELISA assay to measure the elimination kinetics of CPDs, untreated GM00637 fibroblasts showed a normal removal of CPDs after 24 h with 64 % remaining photoproducts. Cells incubated with 5 nM and 100 nM everolimus repaired CPDs similar to untreated cells. However, 0.1 µM cyclosporin A treated GM00637 fibroblasts showed an almost complete inhibition of CPDs removal with 96 % remaining photoproducts after 24 hours (Table 1 right column).
Conclusion
Cyclosporin A leads to a dose-dependent decrease of the repair of UV-induced DNA damages in human cells whereas everolimus 
Introduction
Reactive oxygen species (ROS) play a major role in carcinogenesis but also in the mechanisms of action of radiotherapy and chemotherapy of malignancies. The NAD(P)H-oxidase catalyzes the NAD(P)H-dependent reduction of molecular oxygen (O 2 ) to superoxide (O 2 -. ) from which other aggressive ROS are generated. Among many different functions, ROS play a pivotal role in the defense against microorganisms and in signal transduction. Members of the NAD(P)H oxidase family are present in almost all cell types, however the most common is NOX2 which is highly expressed in phagocytic cells. After stimulation, the regulatory cytosolic components of NOX2 (p40 phox , p47 phox , p67 phox , rac2) are translocated to the membrane-anchored subunits gp91 phox and p22 phox . The big gp91 phox subunit forms the catalytic core of the enzyme and p22 phox is a smaller stabilizing protein.
The assembly of all subunits results in the generation of superoxide.
Variability of NAD(P)H oxidase function has been extensively studied in relation to the amino acid exchange His>Tyr at codon 72 in the membrane-bound p22 phox subunit. In addition, there are many reports indicating associations with clinical phenotypes, in particular cardiovascular diseases. However, the clinical and biochemical findings of 72His>Tyr are controversioal and a potentioal impact of other genetic variants in the corresponding CYBA gene has less been explored. We therefore studied twelve genetic variants in relation to NAD(P)H oxidase function in granulocytes of healthy volunteers. Furthermore, we investigated whether these twelve polymorphisms had an impact on CYBA mRNA and protein expression.
Material and methods
For the measurement of NAD(P)H oxidase activity, 125 healthy volunteers of Caucasian origin participated in this study, 81 in a first exploratory study and 44 in a second independent confirmatory group. ROS formation of isolated granulocytes was recorded after stimulation with phorbol 12-myristate 13-acetate (PMA) by chemiluminescence mediated by L1012. Amounts of p22 phox protein were determined by Western blot using 31 samples (about 10 of each genotype configuration of the SNP CYBA 640A>G) extracted from isolated granulocytes. Since granulocytes contain low amounts of RNA, transcription analysis was conducted with peripheral blood mononuclear cells (PBMCs). Variants for genotyping were selected by two rules, on the one hand variants already reported to be functional in the literature were included and on the other hand tagging SNPs were selected to cover all genetic polymorphisms with a frequency of 5% or more. The polymorphisms were analyzed either by a fluorescence-based primer extension method (SNaPshot ® ), or by pre-designed real time allelic discrimination assays (TaqMan ® ) or by RFLP analysis. Pairwise linkage disequilibrium for the genotyped polymorphisms was visualized by HaploView ® software to delineate blocks of high linkage disequilib- rium for which haplotypes were calculated using PHASE ® software.
Results
We searched for correlations between the CYBA genotypes and enzyme activity representing the phenotype. The strongest signal (p = 0.006) was found for a polymorphism in the 3'-region of CYBA. This polymorphism is termed rs1049255 also known as CYBA 640A>G. Compared to granulocytes isolated from individuals with the AA genotype, those from GG-carriers produced about 28% less ROS [Schirmer et al. 2008] . Moreover, this SNP reached a threshold p-value of 0.05 for false positive discovery independently in both study groups (81 and 44 participants, respectively). A second strong association (p = 0.009) was found with the SNP rs3180279 which is located in intron 5 of CYBA. However, this additional association may only reflect the high degree of linkage disequilibrium between CYBA 640A>G and rs3180279.
We then tested whether haplotypes of SNPs in high linkage disequilibrium (LD) located at the 3'-region of the CYBA gene would give a better characterization of genotype-phenotype relation than single variants do. Conducting this analysis with four variants in high LD (i.e., rs2254073, rs1049255 = CYBA 640A>G, rs1049254, and rs3180279) did not achieve a stronger statistical significance as the CYBA 640A>G SNP alone did. Due to the very similar statistical association of CYBA 640A>G and rs3180279 we aimed to clarify which of those polymorphisms is likely to be functional. Haplotypes differed with respect to enzyme function only when defined specifically by CYBA 640A>G but not by rs3180279. This finding supported the idea that CYBA 640A>G was the causative SNP.
Further evidence for functionality of CYBA 640A>G was gained since this polymorphism was also associated with gene expression. The G-allele, which was related to reduced enzymatic activity (Figure 1a) , exhibited lower amounts of p22 phox protein in granulocytes ( Figure 1b) and CYBA mRNA levels in PBMCs (Figure 1c ).
Conclusion
We found that the CYBA 640A>G single nucleotide polymorphism (rs1049255) was associated with enzyme activity and gene expression. The G-allele carriers showed a reduced enzyme function compared with people carrying the A-allele. A polymorphism located in intron 5 (rs3180279) was also related with enzyme activity due to high linkage disequilibrium with CYBA 640A>G. Haplotype analysis did not reveal a stronger associations compared to the consideration of CYBA 640A>G as a single SNP. Concerning gene expression people carrying the G-allele of the CYBA 640A>G polymorphism showed lower p22 phox protein amounts in granulocytes and lower CYBA transcript levels in PBMCs. The molecular mechanism causing the observed genotype-phenotype relationship of the CYBA 640A>G SNP remains unclear. A possible explanation for the observed allele specific effects can be suggested by the location of the SNP in the 3'-untranslated region. A nucleotide exchange in this region might alter binding sequences of regulatory factors, leading to reduced transcript stability or translation efficiency. The variant studied here may have an impact on the outcome of diseases or therapies ROS are involved in. This has to be analyzed in further clinical studies.
Possible changes in the genomic features
Introduction
Incidence of human malignancies varies significantly with time and between populations may reflect changes in culture and particularly in nutrition and exposure to carcinogens. The incidence of gastric cancer has decreased in developed countries over the last 70 years, but it is still among the most frequent causes of death due to cancer in the world. Reasons for the decrease may be improved hygiene, altered diet and the widespread use of antibiotics, reducing the spread of Helicobacter pylori [Schulz 2005 ] but the decline had already started more than 50 years ago and long before the antibiotic eradication treatment of Helicobacter pylori was possible. H. pylori is a pathogen that plays a major role in the development of gastritis and stomach cancer. Oral-oral and oral-fecal routes of transmission are thought to play a role in the spread of H. pylori. High prevalence of H. pylori is related to nutrition, family history, education level and poor socioeconomic conditions. Historically, it is not exactly known when the human gastric mucosa became colonized with H. pylori and how this influenced the incidence and specific molecular characteristics of gastric cancer.
The aim of the study is to determine differences between the genomic features of historical and modern tumor tissue with regard to changing trigger factors, such as environment and way of living over the last 150 years. In order to detect these differences, mutations in oncogenes and tumor suppressor genes and the occurrence of H. pylori will be investigated from samples of historical pathological archives focusing on gastric cancer. We have two hypotheses. First, types and frequencies of specific mutations found in gastric cancer from today, 50, 100 or more years ago may differ and this may reflect different carcinogens relevant at those times. Second, mutations may differ depending on the H. pylori status of the patients. For this purpose, methods have to be developed to reliably analyze H. pylori infection in historical specimens to obtain data on the frequency of H. pylori colonization of the gastric mucosa over the last century.
The main time independent risk factors for gastric cancer are genetic predisposition, nutrition, and environmental factors. Factors, which have changed in the last century and might lead to a decreased incidence, are possibly the lack of vitamin C, H. pylori and other co-carcinogens such as alcohol, excessive salt and nitrosamines.
Material and methods
Samples were and will be taken from historical tumor specimens of the Federal Pathological Anatomical Museum of Vienna (Austria) and from the Berlin Museum of Medical History of the Charité. Samples are between 50 and 150 years in age and have been stored in formalin filled glass vessels. Since formalin is known to damage DNA, techniques developed in Historical and Forensic Anthropology that are applicable to ancient DNA are suitable. Degraded DNA is characterized by short fragments (100 -300 bp) and low target numbers, which increases the risk of contamination with modern human DNA. In addition to the investigation of tumor mutations, fragment length polymorphisms will be analyzed for individualization and authentication of each specimen. The next steps will be to sequence exons of the gastric cancer related p53 
First results of ancient DNA amplification
The comparison of three different DNA extraction methods from Qiagen (Forensic Protocol, FFPE Protocol (BioRobot EZ1 ® Workstation) and QIAamp ® DNA FFPE Tissue Protocol) revealed no significant differences in DNA yield (Figure 1 ). Based on previous research, the "Forensic Protocol" will be chosen. Not surprisingly, DNA-preservation of samples collected at the Charité, Berlin, within the past 60 years is better than that of samples collected about 100 years ago. Detailed composition of the historically used fixatives is often unknown and complicates the project. Further chemical analyses of these fixatives are ongoing. Different approaches of DNA amplification with a mixtures of different polymerases and other additives to the PCR might help to finally achieve the objectives.
In addition to the stomach, the kidney is also susceptible to changing environmental influences. A further aim will be to investigate the differences in historical and modern tumor tissues in renal cell carcinoma.
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Introduction
Multidrug resistance (MDR) is a major obstacle to successful cancer treatment. One main mechanism by which cells can become resistant to chemotherapy is the expression of ABC transporters that use the energy of ATP hydrolysis to transport a wide range of substances across the cell membrane [Leonhard et al. 2003 ]. The ABC (ATP-binding cassette) family of membrane transport proteins include the best-known mediators of resistance to anticancer drugs. In particular the MDR efflux pumps ABCB1 (P-glycoprotein), ABCC1 (MRP1), ABCC2 (MRP2) and ABCG2 (BCRP, MXR) actively extrude many types of drugs from cancer cells, thereby conferring resistance to those agents [Leslie et al. 2005] . The most typical efflux pump in the cell membrane is the 170-kDa protein ABCB1 (P-gp) encoded by the ABCB1 (or MDR1) gene [Gottesmann et al. 2002] . ABCB1 functions as an energy-dependent drug efflux pump that lowers intercellular concentrations of various anticancer drugs, such as paclitaxel, doxorubicin and vinblastine (Table 1) . As not all multidrug-resistant cells express ABCB1, a search for other efflux pumps was initiated, leading to the discovery of the multidrug-resistance associated protein 1 (MRP1, or ABCC1). ABCC1 is similar in structure (190-kDa) and recognizes neutral and anionic hydrophobic anticancer drugs such as daunorubicin, doxorubicin and etoposide [Gottesmann et al. 2002] . Interestingly this efflux pump also mediates the transport of sulfated metabolites and also of arsenite and antimony ( Table 2 ). The discovery of ABCC1 stimulated a genomic search for homologues, leading to the discovery of eight additional members of the ABCC subfamily of transporters, of which six have been studied in some detail. Like ABCC1, ABCC2-7 also transports various anticancer drugs with broad substrate specificity such as cisplatin, daunorubicin, leucovorin and also glucuronides, sulfates and glutathione conjugates (Table 2) . Some anticancer drugs, such as mitoxantrone, are poor substrates for ABCB1 and ABCC1. Investigation of mitoxantrone resistant cells therefore leads to the identification of a distant ABC transporter family, ABCG2 (BCRP, MXR), which is a homodimer of two halftransporters, each containing an ATP-binding domain at the amino-terminal end of the molecule [Robey et al. 2007] . Substrates for ABCG2 are doxorubicin, daunorubicin and teniposide whose transport are also mediated by ABCB1. This efflux pump, however, more specifically transports irinotecan, topotecan and the new anticancer compounds tomudex, imatinib and gefitinib (Table 1) . Pharmacology and Therapeutics, Vol. 47 -No. 1/2009 (46-48) Extended Abstract 
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Development of chemosensitizers to overcome resistance
Once MDR appears, chemotherapy is not effective even when using high doses of anticancer drugs. A strategy to overcome resistance is to administer substances (MDR modulators or MDR chemosensitizers). Table  3 gives an overview of drugs or natural compounds which have been shown to modulate in vitro or in animal models ABCB1, ABCG2 and ABCC1 [Choi 2005 ]. Unfortunately, none of these compounds is clinically used to overcome MDR in cancer patients as many of these compounds modulate more than one transporter and cause severe side effects Table 3 ). Furthermore, in addition to the expression in tumor cells most of these membrane proteins are also expressed in various organs, such as ABCB1 on the apical surfaces of epithelial cells, in the liver, small intestine, kidney, adrenal gland, pancreatic duct and capillary endothelium of the brain explaining why modulators are rather unspecific. Recently, many natural compounds like flavonoids have been successfully screened as chemosensitizers (Table 3 ). Based on their lower toxicity these compounds may be good candidates for further investigations to overcome MDR in vivo [Choi 2005 ].
Conclusions
Drug resistance caused by ABC transporters remains one of the primary causes of suboptimal outcomes in cancer therapy. Based on broad substrate specificity and on strong interindividual differences in the expression of ABCB1, ABCG2 and ABCC1 -7 screening of patients for the expression of transport proteins prior to therapy is warranted in order to select the best anticancer drug for a more successful outcome. New treatment strategies in the future may also include novel, potent and non toxic modulators in order to prevent drug resistance.
Molecular mechanisms of drug resistance*
Introduction
In oncology, the highly complex phenomenon of drug resistance is characterized by intrinsic or acquired tolerance of malignant cells to xenobiotic stress. Because resistance treatment following drug exposure involves the interplay of anatomic, histological, cellular and molecular factors -all of them characterized by spatial and temporal resolutionour limited understanding of this dynamic process severely compromises our possibility for therapeutic intervention. While it was initially thought that e.g. resistance to 5-fluorouracil (FU) may be explained by a few parameters concerning pyrimidine metabolism or detoxification [Mader et al. 1997] , we have learned that the complexity of this process needs to be addressed by a synoptic view of molecular and cellular processes. This has been underlined by previous work involving the pharmacogenomic alterations associated with various levels of resistance [Schmidt et al. 2004] . Interestingly, this data suggested that resistance to FU may not be explained by a combination of known mechanisms, but relies on the differential expression of a wide molecular repertoire such as e.g. signal transduction, cell adhesion, and cytoskeleton. In this manuscript we provide an overview on past and current work on this topic.
Material and methods
By using chemoresistant model systems of colon cells resistant to low (5 µM), intermediate (25 µM), and high (125 µM) concentrations of FU and genetically altered breast carcinoma cell lines (with mutant p53 and overexpressed ErbB2) [Strasser et al. 2006 ], we investigated metabolic pathways, epigenetic regulations, expression profiling, angiogenetic phenotype, DNA repair mechanisms and apoptotic pathways in order to gain insight of the complexity of the process.
Results
Starting from the observation that fluoropyrimidine converting enzymes contribute to a drug resistance phenotype, the epigenetic regulation of key enzymes such as thymidylate synthase and thymidine phosphorylase was investigated. Only in one out of five enzymes, i.e. thymidine phosphorylase, the promoter methylation pattern indicated a dynamic status between methylated and unmethylated status. DNA repair enzymes such as uracil-DNA glycosylase had some impact on resistance, but only in the low resistance phenotype. There was a distinct pattern of gene expression following the different levels of resistance addressing a wide molecular repertoire. The majority of affected genes during the early stage represented cytoskeleton, signal transduction, and cell adhesion, whereas changes during the intermediate stage involved genes with functions in DNA repair, replication and mitosis. Transition to the high resistance phenotype was associated with little effort for the colon cancer cells (DNA repair and fluoropyrimidine metabolism), but at the cost of reduced angio-attracting capacity for the cells in terms of VEGF secretion [Schönau et al. 2007] . This system, however, remains vulnerable to targeted intervention at the Akt and the mTOR level with Akt-inhibitors or rapamycin. Apoptosis was also achieved in a dose dependent manner using heterodimers of fluorodeoxyuridine (FdUrd) and Ara-C. These novel class of compounds was active in solid as well as in hematological tumor cell systems selected for resistant subclones of the single agents. Using the cellular breast model, heterodimers were shown to circumvent resistance even in cells resistant to FdUrd or Ara-C inducing a concentration-dependent apoptosis. Irrespective of the genetic background of mutant p53 or overexpressed ErbB2, canonical apoptotic pathways such as activation of caspase-7 or PARP were substituted by nucleolar translocation of activated apoptosis inducing factor (AIF) thus offering lines of intervention even in highly resistant cellular subclones.
Conclusion
In summary, anti-cancer drug resistance is characterized by spatial and temporal resolution. Interrogating a wide molecular and cellular repertoire, a cancer cell is particularly challenged at the beginning of the process, whereas the transition to the high-resistance phenotype is less demanding. Despite our incomplete understanding of the complex process, there is space for intervention in order to modulate or even abrogate anti-cancer drug resistance.
Influence of the hOCT2 inhibitor cimetidine
Introduction
The platinum antitumor drug oxaliplatin, [Pt(DACH)(oxalate)] ( Figure 1A ), is frequently used in the treatment of colon and colorectal cancer. However, its efficacy is often limited by inherent or acquired resistance. Causes of resistance can include amongst others a decreased cellular influx [Wang and Lippard 2005 ]. An important prerequisite for understanding this mechanism of resistance is to clarify how oxaliplatin enters the cell. In addition to passive diffusion, recent studies have suggested a contribution of organic cation transporters (OCTs) [Hall et al. 2008] . Accumulation and cytotoxicity of oxaliplatin in human embryonic kidney (HEK) 293 cells transfected with hOCT2 were increased. Transfection of Madin-Darby canine kidney (MDCK) cells with hOCT1 and HEK 293 cells with hOCT3 showed the same effect, but to a lesser extent [Zhang et al. 2006] . These results in transfected kidney cells inspired us to investigate the role of hOCT2 in the accumulation and cytotoxicity of oxaliplatin in the human colorectal adenocarcinoma cell line HCT-8 and its oxaliplatin-resistant variant HCT-8ox. In order to identify the involvement of hOCT2, specific inhibitors are needed although these are unfortunately rare. Since cimetidine, a histamine H 2 -receptor antagonist ( Figure 1A) , has a much higher affinity for hOCT2 than for hOCT1 [Koepsell et al. 2003 ], we have chosen this compound for our experiments.
Material and methods
Cell culture
The human ileocecal colorectal adenocarcinoma cell line HCT-8 and the oxaliplatin-resistant variant HCT-8ox (kindly provided by Dr. R.A. Hilger, University of Essen, Germany) were cultivated in RPMI-1640™ medium with 10% fetal bovine serum, 100 I.E./ml penicillin and 0.1 mg/ml streptomycin at 37°C and under 5% CO 2 .
Cytotoxicity
The cytotoxicity of oxaliplatin was determined using an MTT-based assay [Alley et al. 1988] . Cells were allowed to attach in 96-well plates and were subsequently incubated with oxaliplatin for 72 h. To evaluate the influence of cimetidine on the cytotoxicity of oxaliplatin, cells were preincubated for 6 or 12 h, or co-incubated for 72 h with 1.5 mM cimetidine. The EC 50 values (drug concentration which produces 50% of the maximum possible response) were determined with the GraphPad Prism™ analysis software package (GraphPad Software, San Diego, CA, USA) using non-linear regression (sigmoidal dose response, variable slope).
Cellular platinum accumulation
In order to characterize the influence of cimetidine on the uptake of oxaliplatin, 10 6
Key words oxaliplatin -organic cation transporterscimetidine -uptakeresistance *This extended abstract summarizes a lecture given by I. Buß during the Annual Symposium of the Working Group for Pharmacology in Oncology and Hematology (APOH) of the Central European Society for Anticancer Drug Research (CESAR) held incells were allowed to attach in 6-well plates and incubated up to 24 h with oxaliplatin (20 µM) with and without pre-treatment with 1.5 mM cimetidine for 12 h or with oxaliplatin and 1.5 mM cimetidine simultaneously. After the isolation of the cell pellet, the intracellular platinum concentration was measured by flameless atomic absorption spectrometry (SpectrAA™ Zeeman 220; Varian, Darmstadt, Germany). Platinum concentrations were related to the protein content determined by the bicinchoninic assay (BCA™ Protein Assay Kit, Pierce, Rockford, IL, USA).
Chemical interaction between oxaliplatin and cimetidine
Oxaliplatin (10 mM) and cimetidine (150 mM) were incubated in PBS/DMF mixture (1:1) at 37°C. After 1 h, 2 h, 3 h and 16 h, 195 Pt NMR spectra of the reaction mixture were recorded on a Bruker DPX 300 spectrometer with a 5 mm multi-nucleus probe. The spectra were calibrated with respect to external K 2 PtCl 4 at d = -1,614 ppm. 
Statistical analysis
Statistical analyses were performed using Student's t-test. P-values < 0.05 were considered significant.
Results and discussion
We first studied the effect of cimetidine on the cytotoxicity of oxaliplatin (Table 1) . Pretreatment with cimetidine for 6 and 12 h did not affect the cytotoxic potency of oxaliplatin. However, co-incubation significantly reduced the cytotoxicity of oxaliplatin in both HCT-8 (p = 0.0002) and HCT-8ox cells (p = 0.002). In accordance with these results, a reduction of the cellular platinum accumulation during co-incubation, but not during pre-incubation with cimetidine was observed ( Figure 1B) . Since pre-incubation with cimetidine had no effect and co-incubation significantly affected intracellular platinum concentrations and cytotoxicity, we presupposed that oxaliplatin could react with cimetidine in culture medium, thereby resulting in the reduced cellular accumulation and hence in the reduced cytotoxicity. Monitoring the reaction between oxaliplatin and cimetidine showed that interaction between the compounds is fast, as no peak of oxaliplatin at d = -1,970 ppm could be detected already after 1 h. Instead, a peak at d = -3,245 ppm corresponding to the product of the reaction was found. The chemical shift of this peak indicates a Pt ion to be in an [N 3 S] coordination surrounding, suggesting that [Pt(DACH)(cimetidine)] 2+ was formed. Thus, under the conditions of co-incubation experiments oxaliplatin is bound to cimetidine. To the best of our knowledge, this is the first report about an interaction of oxaliplatin and cimetidine under physiological conditions.
Our data clearly show that the results of the studies, in which a platinum complex is co-incubated with a transporter inhibitor, should be treated with caution. For example, a recent publication reported that co-incubation with cimetidine significantly reduced oxaliplatin accumulation but did not affect cisplatin and carboplatin accumulation [Zhang et al. 2006] . Given rapid interaction between oxaliplatin and cimetidine, reaction of cisplatin and carboplatin with the inhibitor of hOCT2 is also likely. At the first glance, one would expect reduction of cisplatin and carboplatin accumulation, as well as their cytotoxicity. However, it is possible that the product of reaction of cisplatin and carboplatin with cimetidine [Pt(NH 3 ) 2 (cimetidine)] 2+ is readily taken up by the cell, whereas [Pt(DACH)(cimetidine)] 2+ is not. Since organic cation transporters mostly transport molecules with molecular weight below 500 Da [Koepsell et al. 2007] 
Conclusions
Although our results show that co-incubation of oxaliplatin with cimetidine results in reduced cellular accumulation and lower cytotoxicity of oxaliplatin, they do not reveal whether hOCT2 is involved in the cellular uptake of the drug. Under co-incubation conditions, oxaliplatin most likely reacts with cimetidine in culture medium resulting in decreased platinum accumulation and reduced cytotoxicity. This in turn indicates that the results of co-incubation experiments of platinum complexes with cimetidine should be interpreted with caution.
Plasma and cellular pharmacokinetics of
Introduction
Anthracyclines, particularly doxorubicin, are cornerstones of chemotherapy for a wide range of cancers, including hematological malignancies, many types of carcinoma, and soft tissue sarcomas. Anthracyclines are used in the therapy of hematological tumors (e.g. ALL, AML) as well as in the treatment of solid tumors, both curative and palliative. However, the use of anthracyclines is limited by dose-related cardiotoxicity, myelosuppression and other toxicities such as alopecia and fatigue which, while not life-threatening, reduce the therapeutic index of conventional anthracyclines in the palliative setting, especially for elderly patients [Alexanian et al. 1990 , Barlogie et al. 1984 .
Polyethylene glycol liposomal doxorubicin, also known as pegylated doxorubicin, is registered as Caelyx™ in Europe (Essex Pharma, Munich, Germany) and as Doxil ® in the USA (Alza Pharmaceuticals, Moutain View, CA, USA). The encapsulation of doxorubicin by pegylated liposomes prevents its uptake by the reticulo-endothelial system, resulting in a significant prolongation of the serum half-life to around 3 -4 days , Vail et al. 2004 compared to the halflife of conventional doxorubicin averaging about 30 h [Twelves et al. 1991] . As a result, the tissue distribution of doxorubicin is favourably modified after administration of Caelyx™/Doxil ® and thus associated with less myelotoxicity, alopecia and gastrointestinal toxicity as compared to standard formulations of doxorubicin.
Purpose
It was the aim of this study to analyze the plasma levels as well as the cellular uptake of encapsulated and free doxorubicin. For this purpose, Caelyx™ was administered i.v. to patients with advanced hematological malignancies at doses of 20 mg/m 2 and 30 mg/m 2 (equivalent to doxorubicin HCl) within one hour, over 28 days, for as long as patients respond to and tolerate treatment.
Methods
To evaluate the pharmacokinetics of Caelyx™ in patients suffering from hematological tumors, plasma and urine analyses were performed on day 1, 2, 3, 4, 5, 8, 15, 22 and 28 of each cycle. Additionally, spontaneous urine fractions were collected for the first three days, time point and volume of each fraction were documented, and an aliquot of 100 µl urine was separated for the quantification. Resulting PK parameter were compared to conventionally applied doses of 30 mg/m 2 doxorubicin.
Analyses of free doxorubicin as well as Caelyx™ of either plasma or urine were performed as described previously . Using this method, the quantification of doxorubicin, doxorubicinol, and 7-deoxydoxorubicinolon was possible. PK calculations were performed by the use of Kinetica 2000 (InnaPhase Sarl, Champs-sur-Marne, France) and TOPFIT 2.0 (Heinzel G, Woloszczak R, Thomann P, TOPFIT Version 2.0: Pharmacokinetic and Pharmacodynamic Da- Pharmacology and Therapeutics, Vol. 47 -No. 1/2009 (55-57) Extended Abstract ta Analysis System for the PC. Stuttgart, Germany: Gustav Fischer Verlag/VCH Publishers; 1993). In addition, the cellular uptake of doxorubicin was analyzed in single intra-individual comparisons in 4 patients.
Results
Results are based on analyses of 14 patients, receiving 61 administrations of Caelyx™ and 4 applications of conventional doxorubicin, resulting in 323 plasma samples and 155 cell samples.
The pharmacokinetics of Caelyx™ and free doxorubicin are well described by a one compartment distribution. Although the metabolite 7-deoxy-doxorubicinolon was detected in several samples, pharmacokinetic calculations are not available up to now. No Caelyx™, only free doxorubicin, was found to be excreted via the urinary pathway (data not shown).
There is a linear pharmacokinetic behavior for the encapsulated doxorubicin formulation as well as for doxorubicin released from Caelyx™, with a dose-dependent increase of AUC and Cmax with no evidence for an accumulation of the free doxorubicin in plasma up to a dose of 50 mg/m 2 Caelyx™ every 4 weeks. For patients suffering from solid tumors, the mean (terminal) half-life for Caelyx™ was calculated as 3 days, mean residence time (MRT) was in the range of about 5 days, and besides the Vss of 1.5 l, clearance was determined to be less than 1 ml/min . In comparison to these patients, the parameters AUC and terminal half live decreased significantly for the analyzed hematological patient group within this study, whereas CL was increased. There was no detectable renal excretion (CLren) of the intact liposomes, neither in patients with solid, nor with hematological tumors. In addition, the calculated PK parameters for the released doxorubicin gave evidence for an increased area under concentration/time curve (AUC) and (MRT), and a decreased Cmax and clearance (CL), in comparison to conventionally administered free doxorubicin ( Figure  1A ). Cellular uptake of doxorubicin increased after application of Caelyx™, compared to the intra-individual uptake of the equivalent conventional dose of doxorubicin ( Figure 1B) .
Conclusions
Besides the effect of indirect tumor targeting the long circulating pegylated liposomes enable the treatment of potential (micro) metastases and open up the practical use of the anti-angiogenic potential of doxorubicin [Drevs et al. 2004] . Furthermore, the long lasting uptake of doxorubicin into circulating (Figure 1 ) is a novel anti-cancer ruthenium (III) complex with activity against various tumors [Berger et al. 1989 , Hartinger et al. 2005 , Jakupec et al. 2005 . The efficacy has been investigated in a clinical Phase I trial in patients with advanced solid tumors. FFC14A is only the second ruthenium-based anti-cancer agent, after NAMI-A, which has been developed to the stage of clinical trials. Important steps in the mode of action of KP1019 are thought to be the binding to the serum protein transferrin and the transport into the cell via the transferrin pathway. Additionally, the selective activation by reduction in the tumor might contribute to the low side effects observed in in vivo studies. Apoptosis is induced at non-toxic levels via the mitochondrial pathway [Hartinger et al. 2006 , Kratz et al. 1994 . Due to the addition of indazole hydrochloride in a molar ratio of 1.1:1 as a stabilizing agent to the infusion solution, the analysis of its pharmacokinetics is also mandatory as for FF14A.
For the detection of indazole in plasma and urine, we used a validated RP-HPLC method with ultraviolet as well as fluorescence detection. In addition, inductively coupled plasma mass spectrometry (ICP-MS) was used for the quantification of free ruthenium as well as protein and DNA bound fractions.
Purpose
The aim of this study was to analyze the PK of ruthenium as well as indazole in a series of patients treated with FFC14A within a Phase I study. In addition to the quantification of Ru-DNA adducts within peripheral blood leucocytes, the postulated mode of action by transferrin bound ruthenium to plasma proteins was investigated.
Methods
For this purpose 8 patients with advanced solid tumors received FFC14A as an i.v. infusion twice weekly over three weeks. Dose escalation was performed according to an accelerated dose titration design at an infusion rate of 10 ml/min, starting at a total dose of 25 mg. During the early phase of the trial, double dose steps (100% increments) were used. The trial ended with an absolute dose of 600 mg. The infusion was applied on days 1, 4, 8, 11, 15 and 18. FFC14A was reconstituted from the sodium salt and indazolium hydrochloride in a ratio of 1:1.1 to stabilize the infusion solution. The trial drug was prepared immediately before administration. To do this 50 mg of water-free sodium-trans-[tetrachlorobis(1H-indazole) ruthenate (III)] were dissolved in exactly 15 ml isotonic common salt solution and transferred to a sterile container. The total volume of one vial of indazole-hydrochloride (116.5 ml) in a concentration of 0.145 mg/ml was added to the sterile container at room temperature. The solution had to be clear and particle-free. Then it was applied through an intravenous catheter by a use of sterile filter. In order to investigate the pharmacokinetics of the ruthenium complex and indazole, plasma samples were collected before, during and after treatment. After the first and fifth administration rich data sampling was performed. The blood samples were taken directly before and after infusion, at 20, 40 min and 1, 2, 4, 8, 24, 32, 48 and 56 hours after the end of the infusion. Additional blood samples were taken before and after each drug administration on Days 4, 8, 11 and 18 as well as 20, 40 and 60 min after drug administration on Days 4 and 18. Urine sampling was performed continuously from the first to the second, the fifth to the sixth administration and additionally right before each other infusion. Pharmacokinetic analyses for total ruthenium in plasma have been done previously by Lentz et al. [submitted] by the use of atomic absorption spectroscopy. In this investigation, the analysis of ruthenium in plasma (total ruthenium), ultra filtrated plasma (UF, free Ru) and urine as well as of fractionated Ru-proteins and Ru-DNA-adducts was performed by using ICP-MS. The samples were diluted in an aqueous solution containing 0.65% HNO 3 and 0.05% Triton-X-100 and an internal standard. For the quantification of ruthenium a Varian 820 ICP-MS detector was used and volumes of 1.0 ml were injected. For the detection of indazole in plasma and urine a validated RP-HPLC method with ultraviolet as well as fluorescence detection was used. To prove the postulated mechanism of action by formation of a FFC14A-transferrin-complex, plasma proteins were fractionated by the use of a RP-HPLC method, consisting of a TSKgel octadecyl-NPR column (Tosoh Bioscience GmbH, Stuttgart, Germany) as a stationary phase.
Results
To estimate the pharmacokinetic parameters of ruthenium Kinetica 4.1.1 was used (InnaPhase Corporation, Philadelphia, PA, USA). The data fitted best in a two-compartment model. The mean terminal half-life was about 80 h. PK parameters calculated by Jaehde's lab were confirmed [personal communication, Lentz et al., submitted] . In fact, less than 1% of ruthenium was found in the apo-transferrin fraction (Figure 1 ). More than 99% was bound to albumin.
Using the validated high sensitivity ICP-MS method, we were able to detect free levels of ruthenium in ultra filtrated plasma for all applications of FFC14A. First analyses indicate a two-compartment model for free Ru. In total, free drug concentrations were below 0.11% ± 0.32% (mean ± std., n = 253 samples, max = 3.46%, min = 0.01%).
Ru-DNA-addukt formation was analyzed for white blood cells. Even at the lowest dose of 25 mg FFC14A adducts were detectable. There seems to be a saturation of adduct levels, probably explained by the turnover of the cells. At higher dose levels, the yield and quality of the isolated genomic DNA was poor, probably due to serious impairment by Ru-adducts.
The pharmacokinetics of indazole were calculated from ultra filtrated plasma samples. Indazol binds to proteins in about 50%. Furthermore the terminal half life seems to increase with dose (2 h for the 200 mg application, 10 h for the 400 mg and 2 days for the 600 mg application). Urinary excretion was below 0.1 %.
Conclusions
Considering all results, the pharmacokinetics of FFC14A were characterized by a long terminal half-life, a low total CL, small Vss, and very extensive plasma protein binding and low renal excretion. In ultra filtrated plasma it was possible to detect less than 1% of the given ruthenium. Furthermore, protein binding was not detected to circulating transferrin (< 1%). More than 99% of the total ruthenium binds to albumin, so the already described mechanism of action has to be verified.
Ruthenium-DNA-adduct levels were detectable in peripheral leucocytes at all dose levels. Thus, the determination of Ru-DNA adduct levels may be a feasible biomarker for efficacy and/or toxicity in Phase II studies.
The PK of indazole can be described through a two compartment model. First results gave hint for a non-linear behavior. Thus, the PK of FFC14A, especially of indazole, needs to be investigated in more detail.
Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis*
Introduction
Sorafenib (Bay 43-9006 Nexavar ® ) developed by Bayer AG (Leverkusen, Germany) has passed an extended Phase I study program involving a variety of treatment schedules ]. The drug is approved for the treatment of patients with advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Sorafenib is an oral multi-kinase inhibitor with antiproliferative and anti-angiogenic activities, that has been shown to inhibit the activity of the serine/threonine kinases (c-Raf and b-Raf); vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3; platelet-derived growth factor receptor (PDGFR)-a and -b; as well as c-Kit, Flt-3, and RET. It was studied in combination with CPT-11 [Mross et al. 2003 ], oxaliplatin [Kupsch et al. 2005] , and doxorubicin [Richly et al. 2006] , respectively.
Sorafenib has a mean half-life ranging from approximately 25 -48 h. Following oral administration of [14C]-sorafenib tosylate to healthy volunteers, approximately 19% of the dose is excreted in urine, almost exclusively as glucuronide conjugates of parent drug or metabolites; and 77% in feces (50% as unchanged drug). Approximately 17% of circulating radioactivity in plasma was in the form of sorafenib N-oxide [Lathia et al. 2006] . The pharmacokinetics (PK) of sorafenib are characterized by an enterohepatic circulation of the drug. Two mechanisms have been described. 1. Glucuronidation and excretion of the metabolites from the gall bladder into the intestine, cleavage of the glucuronides, and reabsorption of sorafenib. 2. Oxidation and excretion of the metabolites from the gall bladder into the intestine, reduction via bacteria to sorafenib and reabsorption (data on file).
Purpose
Up to now, the feasibility of the application of sorafenib to patients with renal impairment undergoing hemodialysis has not been investigated. Thus, we have analyzed the pharmacokinetics of sorafenib in patients with renal impairment to determine the influence of hemodialysis.
Methods
Up to now, two patients undergoing hemodialysis have been analyzed. Patient 1 received 200 mg sorafenib twice daily (b.i.d). Undergoing hemodialysis, hypertensive side effects were related to the medication of sorafenib. This toxicity could be overcome by dose adjustment. Prior to hemodialysis, the morning dose of sorafenib was left out, compensated by a single 400 mg dose directly after hemodialysis. No blood samples were taken prior to sorafenib therapy. For PK analysis, blood samples were taken every 20 min for 2 h after the application of a morning dose of 200 mg sorafenib, followed by additional hourly blood withdrawals for 6 h. Additional complete PK analysis was performed after administration of a 400 mg dose directly after Pharmacology and Therapeutics, Vol. 47 -No. 1/2009 (61-64) Extended Abstract 
Results
Sorafenib and its metabolites M1 -M5 [Pleiss et al. 2006 ] are detectable in plasma by the used method (data not shown). The detected metabolite M3 is the reported pyridine-N-oxide of sorafenib. Quantification of the metabolites is impossible at this stage due to the lack of reference standards (are requested from Bayer HealthCare). The obtained PK profile of Patient 1 ( Figure 1A ) raised the question of a "normal" profile. We were able to collect blood samples from a patient suffering from hepatocellular carcinoma. Samples were drawn after the 1st application of 400 mg sorafenib. The obtained PK-profile is shown in Figure 1C (Patient 3). Four maxima were detectable. As stated in the product monograph, renal excretion is given to 19% within 14 days after a single application. We were not able to detect sorafenib and its corresponding metabolites M1 -M5 in urine. For this patient, only the glucuronidated form of sorafenib was detectable (data not shown). The calculated low renal excretion of a sorafenib gave no hint of the necessity of a dose adoption.
The PK of a second patient undergoing hemodialysis is shown in Figure 1B . After applications of 200 mg once a day in the morning there was no accumulation detectable from the first dose to the 176th dose of sorafenib. The pharmacokinetics were best calculated using a four segment absorption model with elimination ( Figure 1D ). Blood samples taken on the days of hemodialysis uncovered an effect of sorafenib. Prior to the application of sorafenib and prior to dialysis, reproducible plasma concentrations (trough values) of sorafenib and its metabolites (data not shown) were calculated. The drug was taken 9 minutes after the start of dialysis. At this time point, plasma concentration had already raised to more than 2-fold. Proceeding dialysis, sorafenib concentrations increased continuously, reaching a Cmax 4fold higher than obtained without hemodialysis. These results confirmed our observations for patient 1. Analyses of the biomarker phospho-ERK1/2 within CD7 positive T-cells revealed a slight pharmacodynamic response after 8 days (25% inhibition), and a complete inhibition after 175 days (data not shown).
Conclusions
Using the described analytical method, the PK of sorafenib and its metabolites can be evaluated. The pharmacokinetics of sorafenib are influenced by enterohepatic circulation and are therefore best described by a multi-segment absorption model ( Figure 1D ). Renal excretion of sorafenib and its metabolites (including glucuronidated forms) seems to be low (data not shown). There was no accumulation of sorafenib after daily applications of 200 mg in a patient with renal impairment undergoing hemodialysis. Under the treatment of hemodialysis the plasma concentrations of sorafenib increased significantly. The plasma clearance of sorafenib after hemodialysis has to be investigated in further studies. Up to date, no recommendations for the treatment of cancer patients undergoing hemodialysis can be given.
Results
Thirty-one patients in this study were enrolled. Twenty-seven patients were evaluable for PK calculations of which 13 were treated with PPI and 14 without PPI. PK parameter C max and AUC 0-24h of FT, 5-FU, CDHP and Oxo were calculated (Table 1) . Figure 1 shows typical plasma concentrations vs. time plots. Given are the measured concentrations after first dose (0 -24 h) and last dose of the first cycle (144 -168 h) of a patient under fasting conditions with PPI treatment. The parent compounds are given with Figure 1A . A b.i.d. dosage regimen of S-1 is sufficient for high 5-FU plasma levels opening a bigger therapeutical window in comparison to bolus 5-FU infusional regimen. The effect of CDHP is marked by an ex- Table 1 . PK Parameter S-1 Components FT, CDHP, Oxo, and 5-FU, respectively. Figure 1A . Plasma concentrations of S1 components: measured plasma concentrations of Tegafur, CDHP and oxonic acid, respectively. tended half life of 5-FU. Nevertheless, the catabolites of 5-FU, FUH 2 and FBAL are detectable in presence of CDHP ( Figure 1B) . The inhibitory effect of CDHP on DPD is remarkable as shown with the additional curves of uracil and UH 2 ( Figure 1B ). The formation of FUH 2 as well as UH 2 is decreased. Thus the inhibition on DPD by CDHP is presented by decrease of UH 2 formation and an increase of uracil ( Figure 1C) . The obtained decrease in 5-FU formation (AUC 0-24h ) under feeding conditions was about 12% and significant (p = 0.01).
In addition, a PK/PD model was established to predict biological effective plasma levels of CDHP for a sufficient inhibition of DPD. Therefore the CDHP plasma levels were fitted in an open one compartment model with first-order input and first-order elimination from the central compartment. Using this PK-data, it is possible to compute the effect on Uracil as well as the corresponding UH 2 plasma concentration as the ratio UH 2 /U ( Figure 1C) . We achieved the best fit using the "sigmoid Emax Model" or "HillModel". On the basis of the Hill-Model the required CDHP concentration for a desired uracil or UH 2 concentration is predictable. Next step will be to transfer this model for the 5-FU concentration.
Conclusions
Oxo and CDHP exposure was reduced under feeding compared to fasting conditions, but food intake did not affect the exposure (AUC 0-24h ) of FT. There was a significant decrease in 5-FU formation (AUC 0-24h ) under feeding conditions (p = 0.01). To increase the bioavailability of Oxo, the administration of S-1 under fasting conditions was more effective. PPI administration together with S-1 does not significantly change the bioavailability of S-1. 
Introduction
First-in-man and especially first-of-classin-man clinical trials in oncology represent a challenging issue in clinical research. At the end of the preclinical investigation of a new drug (product) two important documents are available: a) the Investigator's Broschure (IB) and the Investigational Medicinal Product Dossier (IMPD). These documents include all the results about animal toxicity data, animal pharmacokinetics and -dynamics, efficacy data in in vitro and in vivo models as well as the chemistry, stability and production of the new drug. That anticancer drugs are not used in healthy volunteers is common in oncology first-in-man trials. The first humans in such trials are cancer patients with no chance of cure and who have had a series of cytotoxic pretreatments finally resulting in a progressive and often resistant cancer.
As there is a shift from the development of cytotoxic agents towards cytostatic agents it becomes clear, that the main endpoint of Phase I trials with cytotoxic drugs, which was the maximum-tolerated-dose (MTD), becomes questionable since the major endpoint of Phase I trials with cytostatic agents is still the optimal-biological-dose (OBD). Besides these two endpoints are: the full description of the principal dose-limiting-toxicity (DLT) together with the complete toxicity spectrum observed during the trial. A common toxicity criteria (CTC) catalogue has been developed by the NCI for the grading of toxicity and is now in use (Version 3.0). Pharmacokinetic-, -dynamic, genetic and metabolism studies are performed during the Phase I study. The clinical development of new drugs is accompanied by intensive research on biomarkers which have predictive power for e.g. the determination of the OBD or response. Although not the main focus, the evaluation of tumor response is an important part of a Phase I study since nothing is more convincing than an objective tumor response. The Phase I study ends with a recommendation of a dose for Phase II studies (RDPH2) and a decision how to proceed.
Nevertheless there are some issues which are open for an in-depth discussion as there are really some important considerations to be made. Patients always start with a very low drug dose because the starting dose must be safe. Commonly it is one 10th of the LD 10 (lethal dose for 10% of the mice used for the toxicity studies). Patients starting at this low dose level have less chance to response because it is unlikely to expect an anticancer effect at the starting dose. The questions are therefore: can an intraindividual dose escalation be allowed? How often and under which conditions? The next important issue is the dose escalation procedure. It is common use, that one dose escalation step cannot be greater than 100%. Thus doubling the dose is the fastest way to escalate the dose. Dose escalation steps of this magnitude are allowed as long as no toxicity can be observed. In case of toxicity the magnitude of dose escalation is slowing down to the lowest steps which are 30 to 35%. The next issue is how many patients should be treated at each dose level. The minimum is one patient which would have some disadvantages. It can be just by chance to see no toxicity in a patient. Treating one, two or even more patients bears the chance to catch the drugs toxicity more precisely as well as to define the pharmacokinetics and -dynamics with greater accuracy. The problem is that each additional patient slows down the clinical development as there is a waiting period until all data from the last patient are available. The interesting question is: how to come to the RDPH2 with a minimum of patients and a maximum of information (toxicity, pharmacokinetics, biomarker, anticancer efficacy) in the shortest possible time. The following table gives an overview of cytotoxic and cytostatic drugs which were evaluated in 1st-time in-man trials at our department during the last 8 years (Table 1) .
The mean number of patients in Phase I studies with cytostatic agents (all tyrosine kinase inhibitors (TKI's); antiangiogenic agents) was 41 patients with 7 steps, with cytotoxic agents was 31 with 8 steps. The studies with the TKI's, which were all oral drugs, were accompanied with an extended PK and PD program as well as with a large biomarker research program [Mross 2007] . The studies with the cytotoxic drugs (all i.v. drugs) were accompanied with one complete PK after the first infusion [Mross et al. 2004a ,b, Unger et al. 2007 .
For descriptive statistic analysis the minimum of patient numbers per group is three but a larger number would increase the statistical precision. Complex and expensive PK and PD as well as biomarkers makes only sense when the data can be processed with biometric methods.
Conclusions
The goal to perform a first-in-man with all safety aspects and scientific translational research within the shortest possible time and a minimum of patients is the quadrature of a circle. If the data should be strong, precise and convincing the patient number must be sufficient and one patient per dose level is definitely not enough. Three patients per dose level are a minimum in the case of a large translational research program in which dose-response curves should be complete. At the MTD or OBD level expansion of the patient cohort to 6 or more (than restricted to one tumor type) is a common procedure to increase the data basis of the dose recommendations for further studies.
Alternatively, no PK and PD as well as no biomarker measurements can be performed during all dose escalation steps until a toxicity with Grade 2 was observed. Up to this point the dose escalation would be done with 100% increments with only one patient. The more important part of the study would be that from the first Grade 2 toxicity until the DLT which represents the fine tuning of the new drug with respect to the optimal dose. Such a study First-in-man clinical trials 69 Table 1 . Phase I studies with various anticancer drugs. The RDPH2 is given and the dose range evaluated, the number of dose escalation steps and the number of patients included in the study are also listed. would have two parts: one with a rapid dose escalation in just a few patients (intraindividual dose escalation can be allowed) with only observation of toxicity and a second part with a slower dose escalation part (in this part all relevant toxicity data will be documented) and a complete PK&PD and biomarker research program in a sufficient number of patients. This Phase I study design would allow a rapid study progress and the receipt of all necessary scientific data to recommend a dose for Phase II studies on a strong and statistical robust data basis.
